The Medical and Life Sciences Translational Fund (MLSTF) funds proof-of-concept projects at the earliest stages of translation, supporting preliminary work or feasibility studies to establish the viability of an approach. MLSTF is a consolidated fund comprising devolved funding from MRC and Wellcome.
The Novo Nordisk Innovation Fund will also run under the MLSTF umbrella as a pilot programme for 2020. Projects addressing unmet patient need in diabetes and other cardiometabolic disease (obesity, NASH, atherosclerosis, heart failure and chronic kidney disease) as well as within the field of rare endocrine and rare non-malignant blood diseases are eligible to apply for this stream. High priority will be given to projects that will identify and/or robustly validate novel targets in relevant diseases. Researchers with relevant programmes of activity are strongly encouraged to apply to this stream.
The most recent deadline was Monday 15 June 2020.
For more information see the Medical Sciences Division website.